Investigating how estrogen receptor beta can help prevent melanoma
Estrogen receptor beta is a targetable melanoma tumor suppressor
This study is looking at how a specific protein called estrogen receptor beta (ERβ) might help protect against melanoma, a type of skin cancer that affects more men, by understanding how it influences skin cells and the immune system, with the hope of finding new ways to treat this cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-10979162 on NIH RePORTER |
What this research studies
This research explores the role of estrogen receptor beta (ERβ) in melanoma, a type of skin cancer that is more common in men. It aims to understand how ERβ protects against the formation and progression of melanoma by examining its effects on cell differentiation, proliferation, and immune response. The study will utilize a murine model to investigate the mechanisms behind ERβ's tumor suppressor activity and its potential to enhance T cell activation against tumors. By identifying the pathways influenced by ERβ, the research seeks to uncover new therapeutic targets for melanoma treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for melanoma, particularly those with low levels of estrogen receptor beta expression.
Not a fit: Patients with melanoma who do not express estrogen receptor beta or have advanced disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that harness the protective effects of estrogen receptor beta against melanoma.
How similar studies have performed: Previous studies have shown promising results in targeting estrogen receptors for cancer treatment, indicating potential success for this approach.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Burd, Craig J — Ohio State University
- Study coordinator: Burd, Craig J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.